Sample size
The sample size for this study was determined based on real-world data evaluating the effectiveness of sotrovimab in preventing hospitalization in cases of mild-to-moderate COVID-19. The trial results indicated that sotrovimab reduced hospitalization rates to 1% compared to 11.4% in the standard care group (